Product logins

Find logins to all Clarivate products below.


: Healthcare dealmaking

Here you will find relevant articles and insight into all Clarivate related products and news.

How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST] How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST]
Blog February 8, 2022
How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST]
Conversations in Healthcare Healthcare dealmaking Podcast
The evolution of the asset-centric approach in biotech venture capital The evolution of the asset-centric approach in biotech venture capital
Blog June 18, 2021
The evolution of the asset-centric approach in biotech venture capital
Healthcare dealmaking Podcasts Portfolio strategy
Celebrating 30 years of BioWorld Celebrating 30 years of BioWorld
Blog July 1, 2020
Celebrating 30 years of BioWorld
Clinical trials Healthcare dealmaking Research and development
Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018 Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018
Blog March 10, 2020
Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018
Healthcare dealmaking
Report: Biopharma licensing eclipsed $33 billion in Q2 2019 Report: Biopharma licensing eclipsed $33 billion in Q2 2019
Blog October 4, 2019
Report: Biopharma licensing eclipsed $33 billion in Q2 2019
APAC Healthcare dealmaking
Blog July 2, 2019
The AbbVie-Allergan Acquisition and the Road Ahead
Healthcare dealmaking
Oncology landscape stays hot for dealmakers Oncology landscape stays hot for dealmakers
Blog April 29, 2019
Oncology landscape stays hot for dealmakers
Healthcare dealmaking Oncology Portfolio strategy
Neuroscience lures dealmakers despite drug development challenges Neuroscience lures dealmakers despite drug development challenges
Blog January 15, 2019
Neuroscience lures dealmakers despite drug development challenges
Healthcare dealmaking Research and development

Healthcare dealmaking

온디맨드 웨비나 사이트런칭 온디맨드 웨비나 사이트런칭
Blog March 15, 2022
온디맨드 웨비나 사이트런칭
How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST] How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST]
Blog February 8, 2022
How Novo Ventures prioritized their investment strategy during the pandemic [PODCAST]
The evolution of the asset-centric approach in biotech venture capital The evolution of the asset-centric approach in biotech venture capital
Blog June 18, 2021
The evolution of the asset-centric approach in biotech venture capital
Celebrating 30 years of BioWorld Celebrating 30 years of BioWorld
Blog July 1, 2020
Celebrating 30 years of BioWorld
Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018 Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018
Blog March 10, 2020
Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018
Report: Biopharma licensing eclipsed $33 billion in Q2 2019 Report: Biopharma licensing eclipsed $33 billion in Q2 2019
Blog October 4, 2019
Report: Biopharma licensing eclipsed $33 billion in Q2 2019
Blog July 2, 2019
The AbbVie-Allergan Acquisition and the Road Ahead
Oncology landscape stays hot for dealmakers Oncology landscape stays hot for dealmakers
Blog April 29, 2019
Oncology landscape stays hot for dealmakers
Neuroscience lures dealmakers despite drug development challenges Neuroscience lures dealmakers despite drug development challenges
Blog January 15, 2019
Neuroscience lures dealmakers despite drug development challenges
Blog February 2, 2018
Life sciences licensing deals in the fourth quarter of 2017: updates and trends
Blog November 21, 2017
Notable licensing deals in the biopharma industry in Q3 2017